18 Feb 2026
Paul Hastings Strengthens New York Life Sciences Transactions Team with Partner Alan Tamarelli
"Paul Hastings hires Alan Tamarelli as partner and chair of Life Sciences Transactions in New York; he will work in the firm's life sciences transactional practice."
Tamarelli brings deep experience in both private practice and in-house roles leading and advising on technology-driven strategic transactions for biotechnology, pharmaceutical, medical device and other life sciences companies. He joins Paul Hastings from Cooley and previously practiced at Latham & Watkins. He also served for more than a decade as in-house counsel at Merck & Co., where he focused on strategic transactions and, in an earlier role, on resolving significant litigation and regulatory matters. He joins Paul Hastings as a partner and will lead the firm’s life sciences transactions practice in New York.
Tamarelli’s practice focuses on research collaborations and development agreements, intellectual property and technology licensing agreements, and commercial collaborations such as joint ventures, profit-sharing arrangements and co-promotion agreements. He also regularly represents companies in M&A transactions, and on manufacturing, distribution, supply and quality agreements, and clinical trial agreements. Legal 500 US has recognized him as a top adviser for Technology Transactions and Commercial Deals & Contracts. Recent representations include advising Hengrui Pharma on its up to $12.5 billion agreement with GSK and on deals with Braveheart Bio and Merck & Co.; advising Sirius Therapeutics on its collaboration and licensing deal with CRISPR Therapeutics; advising Metsera (now acquired by Pfizer) on in-licensing and acquisition of its core technology from academia; advising Dyno Therapeutics on its research collaboration with Roche; advising Keros Therapeutics on its licensing transaction with Takeda; and advising AviadoBio on its option and licensing deal with Astellas.
Paul Hastings Chair Frank Lopez said the expansion of the firm’s life sciences-specific transactional practices is a strategic priority that will broaden the firm’s integrated life sciences advice and capabilities. Tamarelli said he looks forward to contributing to the firm’s growth and serving clients in the dynamic life sciences sector.